Bangladesh J Pharmacol. 2015; 10: 138-142

Available Online: 21 February 2015; DOI: 10.3329/bjp.v10i1.21203

Effects of fisetin on oxaliplatin-induced neuropathic pain in mice

¹School of Medicine, Hubei University for Nationalities, Enshi, Hubei, 445000, China; ²Institute of Neuropsychiatric Disorder, Hubei University for Nationalities, Enshi, Hubei, 445000, China; ³Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China; ⁴Departments of Neurology and Pneumology, University Hospital of Hubei University for Nationalities, Enshi, Hubei 445000, China.

Abstract

Common chemotherapeutic agents such as oxaliplatin often cause neuropathic pain during cancer treatment in patients. Such neuropathic pain is difficult to treat and responds poorly to common analgesics, which represents a challenging clinical issue. Fisetin is a naturally occurring flavonoid and this study tested the potential anti-hyperalgesic effects of fisetin in a mice model of oxaliplatin-induced neuropathic pain. Fisetin (1-4 mg/kg, i.p.) did not significantly alter the mechanical hypersensitivity in oxaliplatin-treated mice but produced a dose-dependent anti-hyperalgesic effect during repeated treatment. Repeated treatment with fisetin also prevented chronic neuropathic pain-induced depressive-like behavior in a forced swimming test. Both the antihyperalgesic and the antidepressant-like effects of fisetin can be blocked by a selective 5-HT1A receptor antagonist WAY100635 (1 mg/kg). Together, these results demonstrate that fisetin has significant analgesic efficacy against chronic neuropathic pain, which could be a useful analgesic in the management of neuropathic pain.

Introduction

Chemotherapy as a standard treatment for various cancers often leads to a form of unique peripheral neuropathy, which is characterized by provoked and ongoing pain and is increasingly considered as a serious side effect associated with certain chemotherapeutic agents, including taxanes, platinum agents (e.g., oxaliplatin) and vinca alkaloids. Such a side effect varies substantially from 30-75% in cancer patients who receive chemotherapy, depending on the treatment regimens. Importantly, pain is not the only symptom, and other common peripheral sensory symptoms include paresthesias and dysesthesias, numbness and tingling, and sensitivity to touch and temperature. Sometimes motor symptoms are also reported, inclu-ding weakness and gait and balance disturbances (Ross et al., 2002). It has a wide variety of pharmaco-logical activities such as antioxidant (Tordera et al., 1994), anti-allergic (Ravichandran et al., 2011), neuroprotective activities (Zhen et al., 2012). Because antidepressants are frequently used to treat persistent and neuropathic pain, this study examined the potential antinociceptive actions of fisetin in a mice model of chronic neuropathic pain. As monoaminergic system including serotoninergic system is critically involved in pain modulation and proce-ssing, the potential pharmacological mechanism under-lying the antinociceptive effects of fisetin was also studied.

Materials and Methods

Animals: Male C57BL/6 mice weighing 16-22 g (Huazhou University of Science and Technology, Wuhan, China) were acclimated to the temperature, humidity and lighting (12 hours light/dark cycle, lights on at 7:00 AM) controlled vivarium and housed in groups of four for at least one week before testing. The animals had free access to dietary food and water except during the test sessions. All animal experimental protocols were approved by the local Institutional Animal Care and Use Committee, Hubei University of Nationalities. Animals were maintained and experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals (8^th edition, Institute of Laboratory Animal Resources on Life Sciences, National Research Council, National Academy of Sciences, Washington DC). All efforts were made to minimize animal suffering and to reduce the number of animals used.

Drugs: Oxaliplatin and fisetin (Sigma-Aldrich, St. Louis, MO, USA) were dissolved in 5% dextrose (1 mg/mL) and prepared fresh for daily use. WAY100635 (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 0.9% saline. All injections were given intraperitoneally in a volume of 1 mL/100 g of body weight. After habituation to the test environment and baseline measurements of pain sensitivity, mice were randomized to two treatment conditions of either oxaliplatin (3.0 mg/kg) or vehicle (5% dextrose). Using injection volume of 10 mL/kg, mice were treated with daily administration for 5 days, followed by 5 days of rest, for two weekly cycles. Total cumulative dose of 30 mg/kg oxaliplatin over a total of ten injections was used.

Mechanical hyperalgesia measurement: Mechanical hyperalgesia was assessed prior to and 1 day after the last oxaliplatin treatment using Von Frey filaments of varying forces (0.07-4.0 g) applied to the mid-plantar surface of the right hind paw, with each application held until curved for 6 sec using the up-down method (Porsolt et al., 1977). Briefly, mice were individually plunged into vertical Plexiglas cylinders (height: 25 cm; diameter: 10 cm), which were filled with water (depth: 10 cm; temperature: 25 ± 1°C), for 6 min. Mice were deemed immobile when they floated passively, without motion except for making only necessary movements to keep their heads above the water. The immobility time was recorded during the last 4 min of the total 6 min trial.

Locomotor activity test: Commercially available appara-tus was used to measure the locomotor activity of naïve mice treated with vehicle or fisetin (Shandong Academy of Medical Sciences, China), which consisted of four acrylic boxes and in each box there was one pyroelectric infrared sensor 4 cm above the floor. The sensor could detect the movements of the mice through infrared radiation. The apparatus recorded only gross movements of the mice, whereas small movements such as gnawing or grooming could not be differentiated and recorded.

Data analyses: For the antinociceptive studies, data were presented as paw withdrawal threshold (grams) plotted as a function of time (min or days), respectively. Data were analyzed by two-way repeated measures analysis of variance (ANOVA) (time × fisetin treatment or time × oxaliplatin treatment) followed by post hoc Bonferroni test. For the FST data, immobility time was analyzed using one-way ANOVA followed by post hoc Bonferroni test. For the locomotion tests, data were analyzed with one-way ANOVA followed by post hoc Bonferroni test. Differences with p<0.05 were considered statistically significant.

Results

Chronic oxaliplatin treatment (3 mg/kg) led to marked mechanical hyperalgesia in mice as measured by von Frey filament (Figure 1). Paired t-test revealed that oxaliplatin treatment produced a significant decrease in the paw withdrawal threshold (t (7) = 11.24, p<0.0001). In addition, repeated test every 10 min over a period of 100 min did not alter the hyperalgesic condition, which remained significantly lower than the baseline measure-ment prior to oxaliplatin treatment (left, Figure 2). Two-way ANOVA revealed significant main effects of oxaliplatin treatment (F [3, 21] = 94.3, p<0.0001) and time (F [9, 63] = 32.74, p<0.0001). Acute fisetin treatment within the dose range tested (1-4 mg/kg) failed to significantly alter the paw withdrawal threshold in mice (left, Figure 2). Two-way ANOVA failed to reveal significant main effect of fisetin treatment (F [9, 126] = 1.78, p>0.05). Interestingly, twice daily treatment with fisetin progressively reduced mechanical hyperalgesia (right, Figure 2). Two-way ANOVA revealed significant main effects of fisetin treatment (F [2, 14] = 48.48, p<0.0001) and fisetin × day interaction (F [14, 98] = 9.18, p<0.0001). Multiple comparison analysis found that the paw withdrawal threshold was significantly increased starting from day 6 at the daily dose of 2 mg/kg and starting from day 4 at the daily dose of 4 mg/kg. At the dose of 4 mg/kg, the paw withdrawal threshold was completely reversed 8 days after daily treatment.

Figure 1: Paw withdrawal thresholds before and after oxaliplatin treatment in mice (n = 8 per group). ^ap<0.001 as compared to pre-oxaliplatin measurements

Figure 2: Effect of acute (left) and repeated (right) fisetin treatment on measure of mechanical hyperalgesia in oxaliplatin-treated mice (n = 8 per group). ^ap<0.05 as compared to corresponding control data

In order to understand the receptor mechanism underlying the antihyperalgesic actions of fisetin, a dose of the selective 5-HT_1A receptor antagonist WAY100635 (1.0 mg/kg) was studied in combination with 4 mg/kg fisetin (Figure 3). Daily treatment with WAY100635 significantly and almost completely prevented the effect of fisetin for progressively increasing the pain withdrawal threshold. Two-way ANOVA revealed that there were significant main effects of WAY100635 treatment (F [1, 7] =39.36, p<0.0001) and WAY100635 × day interaction (F [7, 49] = 8.24, p<0.0001). Post hoc analysis found that the antihyperalgesic effect of fisetin was significantly decreased at days 5-8.

Figure 3: Effect of WAY100635 on 4 mg/kg fisetin-induced anti-hyperalgesia in mice (n = 8 per group). ^ap<0.05 as compared to corresponding 4 mg/kg fisetin data

Persistent neuropathic pain induced by oxaliplatin led to significant depressive-like behavior as demonstrated by increased immobility time in the FST test (left, Figure 4). Interestingly, repeated fisetin treatment not only reverted such a neuropathic pain condition, it also reverted the depressive-like behavior, demonstrating antidepressant-like activity. One-way ANOVA revealed a significant effect of fisetin dose (F [3, 28] = 14.46, p<0.0001). Post hoc analysis found that the oxaliplatin-treated mice demonstrated a significantly higher immobility time as compared to non-treated control mice, and that repeated 4 mg/kg fisetin-treated mice that also received oxaliplatin treatment demonstrated a significantly lower immobility time.

Figure 4: Effect of repeated fisetin treatment on the duration of immobility in FST in mice (left) and acute fisetin treatment on locomotor activity (right); n = 8 per group; ^ap<0.0001 as compared to non-pain control mice; ^bp<0.0001 as compared to oxaliplatin-treated mice

The potential effect of fisetin treatment on the general locomotor activity in naïve mice was also examined (right, Figure 4). It was found that fisetin failed to significantly alter the spontaneous locomotor activity between the doses of 1 and 4. One-way ANOVA found a significant effect of fisetin dose (F [3, 28] = 0.9, p>0.05). Post hoc analysis revealed no significant differences.

Discussion

In this study, it was found that a naturally occurring flavonoid, fisetin, produced robust anti-hyperalgesic effect in a mouse model of chemotherapy-induced neuropathic pain during repeated but not acute treatment. Along with this antinociceptive effect, repeated fisetin also prevented the development of depressive-like behavior in the mice with neuropathic pain. Then the potential pharmacological mechanism underlying the observed antinociceptive action of fisetin was examined and it was discovered that the effect was primarily mediated through serotoninergic 5-HT_1A recetors. All these data support the potential utility of using fisetin for the control of chronic pain such as chemotherapy-induced neuropathic pain.

Some cancer chemotherapeutic agents including oxaliplatin can cause peripheral and cranial neuropathy in a subpopulation of cancer patients. Several animal models of chemotherapeutic agent-induced neuropathy was developed to mimic this clinical abnormality. Rodents treated with chemotherapeutic agents typically develop thermal and mechanical hyperalgesia. In consistency with the literature, it was found that mice treated with 3 mg/kg intermittently developed a reliable mechanical hyperalgesia as measured by von Frey filament test. When administered acutely, it was found that fisetin produced no significant effect in decreasing mechanical hyperalgesia. Interestingly, twice daily treatment with fisetin produced a progressive and clear antinociceptive action in a dose-dependent manner. At larger doses it completely reversed the mechanical hyperalgesia. Importantly, this elevated mechanical pain threshold appears to be a curative effect, as the measurement was conducted 4 hours after fisetin administration. Further experiment can conclusively address this question by extended pain testing with no more fisetin treatment. It is important to note that the observed anti-hyperalgesic effects were not due to general behavioral suppression because fisetin did not significantly alter the locomotor activity in mice even at the largest tested dose. It was also observed that fisetin also prevented the development of depressive-like symptoms as evidenced by reduced immobility duration in the FST, a widely used mice model for the screening of antidepressants. Because fisetin possesses antidepressant-like activity in healthy animals (Li, 2014).

In order to begin to understand the pharmacological mechanisms of fisetin-induced antinociception, next experiment examined the involvement of 5-HT_1A receptors because 5-HT_1A receptors are critically involved in the modulation of chronic pain (Colpaert, 2006). It was found that pharmacological blockade of 5-HT_1A receptors almost completely prevented repeated fisetin-induced antinociception. This finding is valuable in the guidance of future studies examining other effects fisetin. Despite these results, other mechanisms may also participate in fisetin-induced pain modulation, particular its antioxidant and anti-inflammatory activities (Tordera et al., 1994; Khan et al., 2013).

In summary, this study for the first time demonstrated that fisetin has potent antinociceptive and antidepressant-like effects in a mouse model of chemotherapeutic agent-induced neuropathic pain, without apparent adverse effects (motor impairment).

References

Cheong H, Ryu SY, Oak MH, Cheon SH, Yoo GS, Kim KM. Studies of structure activity relationship of flavonoids for the anti-allergic actions. Arch Pharm Res. 21998; 1: 478-80.

Colpaert FC. 5-HT(1A) receptor activation: New molecular and neuroadaptive mechanisms of pain relief. Curr Opin Investig Drugs. 2006; 7: 40-47.

Dixon WJ. Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol. 1980; 20: 441-62.

Khan N, Syed DN, Ahmad N, Mukhtar H. Fisetin: A dietary antioxidant for health promotion. Antioxid Redox Signal. 2013; 19: 151-62.

Li JX. Pain and depression comorbidity: A preclinical perspective. Behav Brain Res. 2015; 276: 92-98.

Patel MY, Panchal HV, Ghribi O, Benzeroual KE. The neuroprotective effect of fisetin in the MPTP model of Parkinson's disease. J Parkinsons Dis. 2012; 2: 287-302.

Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: A primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977; 229: 327-36.

Ravichandran N, Suresh G, Ramesh B, Siva GV. Fisetin, a novel flavonol attenuates benzo(a)pyrene-induced lung carcinogenesis in Swiss albino mice. Food Chem Toxicol. 2011; 49: 1141-47.

Ross JA, Kasum CM. Dietary flavonoids: Bioavailability, metabolic effects, and safety. Annu Rev Nutr. 2002; 22: 19-34.

Tordera M, Ferrandiz ML, Alcaraz MJ. Influence of anti-inflammatory flavonoids on degranulation and arachidonic acid release in rat neutrophils. J Biosci. 1994; 49: 235-40.

Visovsky C, Collins M, Abbott L, Aschenbrenner J, Hart C. Putting evidence into practice: Evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs. 2007; 11: 901-13.

Zhen L, Zhu J, Zhao X, Huang W, An Y, Li S, Du X, Lin M, Wang Q, Xu Y, Pan J. The antidepressant-like effect of fisetin involves the serotonergic and noradrenergic system. Behav Brain Res. 2012; 228: 359-66.